Genmab A/S (GNMSF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genmab A/S (GNMSF) trades at $273.50 with AI Score 55/100 (Grade B). Genmab A/S is a biotechnology company specializing in the creation and development of antibody therapeutics for cancer and other diseases. Market cap: $16.79B, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for GNMSF: GNMSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNMSF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
GNMSF: 2/7 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Genmab A/S (GNMSF) Healthcare & Pipeline Overview
Genmab A/S, a Danish biotechnology firm, focuses on developing innovative antibody therapeutics for cancer and other diseases. With a diverse portfolio of marketed products like DARZALEX and a robust pipeline, Genmab competes in the global biotechnology market, leveraging strategic collaborations to expand its reach and development capabilities.
What Is the Investment Thesis for GNMSF?
Genmab A/S presents a notable research candidate within the biotechnology sector, driven by its innovative antibody therapeutics platform and strong pipeline. The company's marketed products, including DARZALEX, generate significant revenue, contributing to a profit margin of 16.7% and a gross margin of 93.6%. Growth catalysts include the continued expansion of DARZALEX in multiple myeloma and other indications, as well as the potential approval and commercialization of pipeline assets like epcoritamab. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. With a market capitalization of $16.79B and a P/E ratio of 25.88, Genmab's valuation reflects its growth potential and established market position. The company's beta of 0.75 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
GNMSF Key Highlights
- Market capitalization of $16.79B, reflecting investor confidence in its antibody therapeutics platform.
- Profit margin of 16.7%, indicating efficient operations and strong profitability.
- Gross margin of 93.6%, highlighting the high value of its products and effective cost management.
- P/E ratio of 25.88, suggesting a premium valuation based on future growth expectations.
- Beta of 0.75, indicating lower volatility compared to the broader market.
Who Are GNMSF's Competitors?
GNMSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALPMF Astellas Pharma Inc. | $14.60 | +3.18% | $26.16B | 58 |
| ALPMY Astellas Pharma Inc. | $13.63 | +2.48% | $24.42B | 55 |
| BMXXY bioMérieux S.A. | $7.53 | -6.98% | $8.88B | 46 |
| GIKLY Grifols, S.A. | $4.77 | -6.47% | $12.54B | 48 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNMSF's Key Strengths?
- Innovative antibody therapeutics platform.
- Strong pipeline of products in development.
- Established market presence with marketed products.
- Strategic collaborations with leading pharmaceutical companies.
What Are GNMSF's Weaknesses?
- Reliance on key products like DARZALEX.
- High R&D spending.
- Dependence on collaborations for commercialization.
- Exposure to clinical trial risks.
What Could Drive GNMSF Stock Higher?
- Continued expansion of DARZALEX in multiple myeloma and other indications.
- Potential approval and commercialization of epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia.
- Advancement of pipeline assets through clinical trials.
- Strategic collaborations with leading pharmaceutical and biotechnology companies.
- Potential for geographic expansion into new markets.
What Are the Key Risks for GNMSF?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other biotechnology companies.
- Patent expirations.
- Reliance on key products like DARZALEX.
What Are the Growth Opportunities for GNMSF?
- Expansion of DARZALEX: DARZALEX, Genmab's leading product for multiple myeloma, has significant growth potential through label expansions and increased market penetration. The global multiple myeloma market is projected to reach $37.5 billion by 2028, providing a substantial opportunity for Genmab to increase its revenue. The company is actively pursuing clinical trials to evaluate DARZALEX in new indications and combinations, which could further drive growth.
- Commercialization of Epcoritamab: Epcoritamab, a bispecific antibody being developed in collaboration with AbbVie, has the potential to become a significant growth driver for Genmab. Epcoritamab targets relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The market for lymphoma treatments is expected to grow, offering a substantial opportunity for Epcoritamab upon regulatory approval. The drug is currently under review by regulatory agencies.
- Advancement of Pipeline Assets: Genmab has a robust pipeline of antibody therapeutics in various stages of development, targeting a range of diseases. The successful advancement and commercialization of these pipeline assets could significantly expand Genmab's revenue base and market presence. The company's pipeline includes products such as Teclistamab, Camidanlumab tesirine, and several other preclinical and clinical programs.
- Strategic Collaborations: Genmab's strategic collaborations with leading pharmaceutical and biotechnology companies provide access to external expertise, resources, and markets. These collaborations can accelerate the development and commercialization of Genmab's antibody therapeutics and expand its global reach. The company's collaborations with AbbVie, Janssen, and other partners are expected to contribute to its long-term growth.
- Geographic Expansion: Genmab has the opportunity to expand its geographic presence and market its products in new regions. The company currently operates primarily in Denmark, but its products are marketed globally through partnerships. Expanding into new markets, such as Asia and Latin America, could significantly increase Genmab's revenue and market share. The company may need to establish local infrastructure and partnerships to succeed in these new markets.
What Opportunities Does GNMSF Have?
- Expansion of DARZALEX into new indications.
- Commercialization of pipeline assets like epcoritamab.
- Geographic expansion into new markets.
- Strategic acquisitions and partnerships.
What Threats Does GNMSF Face?
- Competition from other biotechnology companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Patent expirations.
What Are GNMSF's Competitive Advantages?
- Proprietary antibody therapeutics platform.
- Strong pipeline of innovative products.
- Strategic collaborations with leading pharmaceutical companies.
- Established market presence with marketed products like DARZALEX.
What Does GNMSF Do?
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab A/S is a biotechnology company dedicated to creating and developing differentiated antibody therapeutics for the treatment of cancer and other diseases. The company's initial focus was on developing human monoclonal antibodies, and it has since expanded its portfolio through strategic collaborations and internal research and development efforts. Genmab's marketed products include DARZALEX (daratumumab) for multiple myeloma (MM), teprotumumab for thyroid eye disease, ofatumurnab for chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Genmab's pipeline includes a range of products in various stages of development, targeting hematological malignancies and solid tumors. These include GEN1047, tisotumab vedotin (co-developed with Seagen Inc.), DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB, Epcoritamab (developed in collaboration with AbbVie), HexaBody-CD38, and DuoHexaBody-CD37. The company also has several products in Phase 2 clinical trials, such as Teclistamab, Camidanlumab tesirine, JNJ-64007957, JNJ-64407564, PRV-015, Mim8, and Lu AF82422. Genmab has established collaborations with several leading pharmaceutical and biotechnology companies, including CureVac AG, AbbVie, BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. These collaborations enable Genmab to leverage external expertise and resources to accelerate the development and commercialization of its antibody therapeutics. Genmab operates primarily in Denmark, with a global reach through its partnerships and marketed products.
What Products and Services Does GNMSF Offer?
- Develops antibody therapeutics for cancer and other diseases.
- Markets DARZALEX for the treatment of multiple myeloma (MM).
- Markets teprotumumab for the treatment of thyroid eye disease.
- Markets ofatumurnab for the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis.
- Markets Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
- Develops products for treating hematological malignancies and solid tumors.
- Collaborates with other companies to co-develop and commercialize antibody therapeutics.
How Does GNMSF Make Money?
- Develops and commercializes antibody therapeutics.
- Generates revenue through product sales and royalties.
- Collaborates with other companies to co-develop and commercialize products.
- Out-licenses its technology and products to generate revenue.
What Industry Does GNMSF Operate In?
Genmab A/S operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The global biotechnology market is experiencing substantial growth, driven by increasing demand for novel therapeutics, advancements in antibody engineering, and a growing prevalence of cancer and other diseases. Genmab competes with other biotechnology companies, including ALPMF (Alphamab Oncology), ALPMY (Alphamab Oncology), BMXXY (BioMaxx Pharmaceuticals), GIKLY (Ginkgo Bioworks Holdings), and IVBXF (Invex Therapeutics), in the development and commercialization of antibody therapeutics. The company's strategic collaborations and differentiated technology platform position it favorably within the industry.
Who Are GNMSF's Key Customers?
- Patients with cancer and other diseases.
- Hospitals and clinics.
- Pharmaceutical companies.
- Healthcare providers.
ROE 15%Key Financial Metrics
Return on equity for Genmab A/S stands at 14.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.6%, showing how much profit it generates from its asset base. GNMSF trades at a trailing price-to-earnings ratio of 18.90, below the Healthcare sector average of ~23x. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.3%, the inverse of the P/E and a quick read on earnings relative to price.
Genmab A/S (GNMSF) Valuation Context
Valued at $16.79B, GNMSF is classified as a large-cap stock. Relative to its peer group, GNMSF's quantitative score of 55/100 is roughly in line with the peer average of 55/100.
Company Profile
Genmab A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Copenhagen, DK. The company is led by CEO Jan van de Winkel. GNMSF has traded publicly since 2010.
F-Score 5/9Financial Health
Genmab A/S's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 11.16 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Genmab A/S revenue of about $4.33B for fiscal 2026, with EPS near $11.35. The estimate reflects 22 contributing analysts.
GNMSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Genmab's future prospects, indicating that those closest to the company believe in its potential growth.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative pipeline and potential breakthroughs in cancer treatments.
- Analysts are increasingly recognizing Genmab's strategic partnerships, which bolster its research capabilities and market reach.
- Recent clinical trial results have generated excitement, reinforcing the belief that Genmab is on the verge of significant advancements in therapeutic options.
Bear Case
- Concerns about market competition are growing, as new entrants in the biotech space could challenge Genmab's market share and pricing power.
- Some community members express skepticism regarding the timelines of Genmab's drug development, fearing delays could impact investor sentiment.
- Recent regulatory scrutiny in the biotech sector has created a cautious atmosphere, leading to apprehension about future approvals for Genmab's products.
- A portion of the market remains wary of the volatility typically associated with biotech stocks, particularly in light of broader economic uncertainties.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GNMSF Latest News
No recent news available for GNMSF.
GNMSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNMSF.
Price Targets
Wall Street price target analysis for GNMSF.
GNMSF MoonshotScore
What does this score mean?
The MoonshotScore rates GNMSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jan van de Winkel
CEO
Jan van de Winkel is the CEO of Genmab A/S. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions and has a strong track record in drug development and commercialization. Van de Winkel's expertise spans from early-stage research to late-stage clinical development and market access. He is known for his strategic vision and ability to drive innovation within the biotechnology sector.
Track Record: Under Jan van de Winkel's leadership, Genmab A/S has achieved significant milestones, including the successful development and commercialization of DARZALEX and other antibody therapeutics. He has overseen the expansion of Genmab's pipeline and the establishment of strategic collaborations with leading pharmaceutical companies. Van de Winkel's leadership has been instrumental in driving Genmab's growth and establishing its position as a leading biotechnology company.
GNMSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Genmab A/S (GNMSF) may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure, making it difficult to assess the company's financial health.
- Lower liquidity, leading to wider bid-ask spreads and greater price volatility.
- Less regulatory oversight compared to companies listed on major exchanges.
- Potential for fraud or manipulation due to the lack of stringent listing requirements.
- Higher risk of delisting or going out of business.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's liquidity and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established partnerships with reputable pharmaceutical companies.
- Marketed products with regulatory approvals.
- Experienced management team with a track record in the biotechnology industry.
- Presence in a regulated industry (healthcare).
- Publicly available information and press releases.
What Investors Ask About Genmab A/S (GNMSF) — Healthcare
What does Genmab A/S do?
Genmab A/S is a biotechnology company focused on the creation and development of antibody therapeutics for the treatment of cancer and other diseases. The company's business model revolves around discovering, developing, and commercializing innovative antibody-based therapies. Genmab generates revenue through product sales, royalties from partnered programs, and upfront and milestone payments from collaborations. Its marketed products, including DARZALEX, teprotumumab, ofatumurnab, and Amivantamab, target various diseases and contribute to its market position as a leading antibody therapeutics company.
What are the main risks for GNMSF?
The main risks for Genmab A/S include clinical trial failures, regulatory hurdles, competition from other biotechnology companies, patent expirations, and reliance on key products like DARZALEX. Clinical trial failures could delay or halt the development of pipeline assets, while regulatory hurdles could delay or prevent the approval of new products. Competition from other companies could erode market share and pricing power. Patent expirations could lead to generic competition and reduced revenue. Reliance on key products like DARZALEX makes the company vulnerable to any setbacks or challenges related to that product.
What are the key factors to evaluate for GNMSF?
Genmab A/S (GNMSF) holds an AI score of 55/100 (moderate). Not financial advice.
How frequently does GNMSF data refresh on this page?
GNMSF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GNMSF's recent stock price performance?
Genmab A/S (GNMSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative antibody therapeutics platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNMSF overvalued or undervalued right now?
Valuing Genmab A/S (GNMSF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GNMSF?
Before investing in Genmab A/S (GNMSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNMSF to a portfolio?
Key strength of Genmab A/S (GNMSF): Innovative antibody therapeutics platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for GNMSF.
- OTC market data may be less reliable than exchange-listed data.